Navigation Links
Innocoll Provides an Update on its Range of Advanced Wound Care and Related Collagen-based Products
Date:9/19/2011

ASHBURN, Va., Sept. 19, 2011 /PRNewswire/ -- Innocoll, Inc. announced the following update for its range of advanced wound care and related collagen-based products. Based on a series of recent regulatory approvals and product listings, Innocoll has added six more products in a variety of sponge, film, bilayer, powder, gel and spray formats that are available for commercialization in the US, EU and other markets such as Canada and New Zealand. These products include:  

  • CollaCare®, a range of advanced bioactive wound dressings for the management of chronic and acute wounds available in sponge, film and powder formats.
  • CollaCare® Dental, a lyophilized collagen matrix for the management of oral wounds including periodontal and other dental surgical wounds.  
  • Collexa®, an advanced bilayer wound dressing for the management of heavily exudating chronic wounds and burns.
  • Lidocoll®, an OTC topical analgesic available in collagen-based spray and gel formats containing 4% lidocaine hydrochloride for the relief of pain associated with minor burns, cuts, and skin irritations.
  • CollaGentle™, a collagen-based spray for skin conditioning and moisturizing.
  • Zorpreva™, a series of collagen-based absorbable hemostats for use in surgery including maxillofacial and dental surgeries.

Commenting on the update, Dr. Michael Myers, Innocoll's President and CEO said, "We have successfully expanded our portfolio of collagen-based products to include a wide range of presentations and applications. We are actively preparing for the commercialization of these products in the near future."

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx®, CollaFilm®, DermaSil™ and Liquicoll®. Approved products based on the Company's technologies include: Collatamp® G, Septocoll®, Collieva®, CollaCare®, Collexa®, Zorpreva™, and LidoColl®.

Other products in clinical and regulatory development include: CollaRx® Gentamicin Surgical Implant in phase 3 for prevention of surgical wound infections, Cogenzia® in phase 3 for the adjuvant treatment of infected diabetic foot ulcers, Xaracoll in phase 2b for the management of post-operative pain, and CollaGUARD®, for the prevention of surgical adhesions, which has been submitted for approval in the EU. For more information, please visit www.innocollinc.com.


'/>"/>
SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Innocoll Announces Top-line Results from its Phase 2 Clinical Trial Investigating XaraColl® for the Management of Post-operative Pain and Receives "Notice of Allowability" for XaraColl U.S. Patent Application
2. Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
3. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
4. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
5. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
8. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
10. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
11. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... COPENHAGEN, Denmark , Oct. 2, 2017 The ... tool in the struggle to reverse the tide of prescription ... plan for regulating their medicine intake and stepping down their ... is set to launch in December 2017; the first 100,000 ... access. Learn more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate ... primary prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many ... event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids ... of all ages; it is a non-competitive, non-timed event, which is all about having ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
Breaking Medicine News(10 mins):